What is HC Wainwright’s Forecast for DNLI FY2026 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for Denali Therapeutics in a research note issued on Wednesday, November 4th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($1.61) for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.62) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same quarter in the prior year, the company earned ($0.74) EPS.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Thursday, October 15th. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research note on Wednesday. B. Riley Financial raised their target price on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. UBS Group lifted their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Morgan Stanley lifted their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $36.15.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $19.72 on Friday. The stock’s fifty day simple moving average is $20.25 and its 200 day simple moving average is $21.26. The company has a current ratio of 6.21, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.16 billion, a PE ratio of -11.40 and a beta of 1.08. Denali Therapeutics has a 12 month low of $13.75 and a 12 month high of $27.30.

Insider Buying and Selling

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently modified their holdings of the business. Pier 88 Investment Partners LLC grew its holdings in shares of Denali Therapeutics by 27.6% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 16,200 shares of the company’s stock valued at $335,000 after acquiring an additional 3,500 shares in the last quarter. Alps Advisors Inc. raised its holdings in Denali Therapeutics by 32.0% during the third quarter. Alps Advisors Inc. now owns 211,772 shares of the company’s stock worth $4,377,000 after acquiring an additional 51,394 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Denali Therapeutics during the third quarter worth about $169,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in Denali Therapeutics by 237.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 48,300 shares of the company’s stock valued at $998,000 after purchasing an additional 34,000 shares during the last quarter. Finally, Manchester Capital Management LLC boosted its position in Denali Therapeutics by 5,505.6% during the third quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock valued at $42,000 after purchasing an additional 1,982 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s Q3 earnings beat expectations, while Avlayah sales reportedly rose nearly fivefold and reimbursement coverage expanded. The company also has several pipeline catalysts approaching, giving investors reasons to focus on future growth. Zacks article
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an Overweight rating; Wedbush also lifted its target, to $24, with an Outperform rating. These target increases suggest those analysts see potential upside. Analyst target report
• Neutral Sentiment: HC Wainwright’s estimates project ongoing losses in the coming years, including a $0.62-per-share loss in Q4 2026, but a narrower $0.14 loss in 2030. These are analyst forecasts, not company results, and indicate that a path toward profitability may take time.
• Negative Sentiment: Despite the earnings beat, investors may weigh Denali’s continuing expected losses and valuation against its commercial growth and pipeline prospects. Yahoo Finance article

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.